Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
ESMO Open
|
June 12, 2025
The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials
D Hlauschek, C Fesl, M Gnant
The British Journal of Surgery
|
April 18, 2018
Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy
M Schindl, R Függer, P Götzinger, et al.
ESMO Open
|
August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
M Filipits, M Rudas, C F Singer, et al.
ESMO Open
|
April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
N Dobrić, S O Hasenleithner, C Suppan, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
ESMO Open
|
June 12, 2025
The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials
D Hlauschek, C Fesl, M Gnant
The British Journal of Surgery
|
April 18, 2018
Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy
M Schindl, R Függer, P Götzinger, et al.
ESMO Open
|
August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
M Filipits, M Rudas, C F Singer, et al.
ESMO Open
|
April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
N Dobrić, S O Hasenleithner, C Suppan, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
Page
of 1